21945Orig1s000 - Food and Drug Administration
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
21945Orig1s000
MEDICAL REVIEW(S)
Clinical Review Barbara Wesley NDA 21-945 17-alpha hydroxyprogesterone caproate 3 February 2011
CLINICAL REVIEW
Application Type Application Number(s)
Priority or Standard Submit Date(s)
Received Date(s) PDUFA Goal Date
Division / Office
Reviewer Name(s) Review Completion Date
Established Name (Proposed) Trade Name
Therapeutic Class Applicant
Formulation(s) Dosing Regimen
Indication(s)
Intended Population(s)
NDA 21-945 Priority 12 July 2010 13 July 2010 13 April 2011 Division of Reproductive and Urologic Products Barbara Wesley, M.D., M.P.H. 3 February 2011 hydroxyprogesterone caproate Makena Progestin Hologic Inc. Injectable (Intramuscular - IM) 250 mg (1 mL) weekly from between 16 weeks, 0 days, and 20 weeks 6 days to 37 weeks of gestation or until delivery Reduction of the Risk of Preterm Birth Pregnant women with a history of at least one spontaneous singleton preterm birth
Reference ID: 2900781
Primary Medical Officer Review Barbara Wesley, M.D., M.P.H. NDA 21-945 17-alpha hydroxyprogesterone caproate Final 3 February 2011
Table of Contents
1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT.............................................. 5
1.1 Recommendation on Regulatory Action .......................................................................... 5 1.2 Risk Benefit Assessment .................................................................................................. 5
1.2.1 Efficacy ..................................................................................................................... 6 1.2.2 Safety......................................................................................................................... 7 1.2.3 Summary ................................................................................................................... 8 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies................ 9 1.4 Recommendations for Postmarket Requirements and Commitments .............................. 9
2 INTRODUCTION AND REGULATORY BACKGROUND.......................................... 10
2.1 Product Information........................................................................................................ 10 2.2 Tables of Currently Available Treatments for Proposed Indications ............................. 11 2.3 Availability of Proposed Active Ingredient in the United States ................................... 12 2.4 Important Safety Issues with Consideration to Related Drugs....................................... 12
2.4.1 Castor Oil ................................................................................................................ 12 2.5 Summary of Previous Regulatory Activity .................................................................... 13
2.5.1 Pre-NDA Activity.................................................................................................... 13 2.5.2 Regulatory Summary and NDA Actions................................................................. 14 2.5.3 Studies to Support NDA 21-945 (Original NDA Submission April 14, 2006)....... 18 2.5.4 Advisory Committee (August 29, 2006) ................................................................. 28 2.5.5 Literature ? Late Preterm Births.............................................................................. 30
3 ETHICS AND GOOD CLINICAL PRACTICES ............................................................ 32
3.1 Submission Quality and Integrity ................................................................................... 32 3.1.1 Institutional Review/Ethics/Consent Form: ............................................................ 32
3.2 Compliance with Good Clinical Practices...................................................................... 32 3.3 Financial Disclosures...................................................................................................... 33
4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES...................................................................................................................... 33
4.1 Chemistry Manufacturing and Controls ......................................................................... 33 4.2 Clinical Microbiology..................................................................................................... 34 4.3 Preclinical Pharmacology/Toxicology ........................................................................... 34 4.4 Clinical Pharmacology ................................................................................................... 34
5 SOURCES OF CLINICAL DATA..................................................................................... 36
6 REVIEW OF EFFICACY .................................................................................................. 36
6.1 Indication ........................................................................................................................ 36 6.1.1 Methods ................................................................................................................... 36 6.1.2 Primary Endpoint(s) ................................................................................................ 36
Reference ID: 2900781
2
Primary Medical Officer Review Barbara Wesley, M.D., M.P.H. NDA 21-945 17-alpha hydroxyprogesterone caproate Final 3 February 2011
6.1.3 Secondary Endpoints(s)........................................................................................... 37 6.1.4 Other Endpoints....................................................................................................... 38 6.1.5 Study Design ........................................................................................................... 38
7 REVIEW OF SAFETY ....................................................................................................... 47
7.7 Additional Submissions/Safety Issues............................................................................ 47 7.7.1 Data Safety Monitoring Board (DSMB) ................................................................. 47 7.7.2 Recent Safety Literature .......................................................................................... 48 7.7.3 Follow-up Study (17P-FU-004) .............................................................................. 49 7.7.4 Safety Update .......................................................................................................... 50
8 POSTMARKET EXPERIENCE........................................................................................ 51
9 APPENDICES...................................................................................................................... 52
9.1 Labeling Recommendations ........................................................................................... 52 9.2 Bibliography ................................................................................................................... 52
Reference ID: 2900781
3
Primary Medical Officer Review Barbara Wesley, M.D., M.P.H. NDA 21-945 17-alpha hydroxyprogesterone caproate Final 3 February 2011
Table of Tables
Table 1 Proportion of Subjects with Delivery at ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- international iec standard 60945
- 21945orig1s000 food and drug administration
- series formulas
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 total fws
- department of health pharmacy quality assurance commission
- blu 945 a highly potent and selective 4th generation egfr
- maxtester 940 945 telco olts
- 1 1 2 3 42 42 ˆ 2 2 56 27 3˜ 2 255 823˚ 945
- Êw70 0 3 fit l 2 3 4 5 6 1 2 3 4
- math 113 hw 8 solutions colorado state university
Related searches
- pectin and drug testing
- baking soda and drug test
- frozen urine and drug testing
- certo and drug testing
- meth and drug test
- baking soda and drug tests
- baking soda and drug use
- heroin metabolites and drug tests
- mmr and varicella administration guidelines
- food and drink trivia questions and answers
- food and drug recalls 2019
- alcohol and drug consent forms